Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Sponsor

The University of Texas Health Science Center at San Antonio (Other)

Overall Status

Recruiting

CT.gov ID

NCT02969798

Collaborator

American Diabetes Association (Other), AstraZeneca (Industry), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH)

700

Enrollment

Location

Arms

126

Duration (Months)

5.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus, Type 2 Impaired Glucose Tolerance (IGT) Impaired Fasting Glucose (IFG)	Drug: Dapagliflozin Drug: Saxagliptin Drug: Pioglitazone Drug: Metformin	N/A

Detailed Description

SPECIFIC AIMS:

To examine the effect of the following pharmacologic interventions on beta cell function, insulin sensitivity, and glucose tolerance status in individuals with isolated impaired glucose tolerance (IGT): (i) treatment with the renal Sodium-glucose co-transporter 2 (SGLT2) inhibitor inhibitor, dapagliflozin; (ii) treatment with the inhibitors of dipeptidyl peptidase 4, also DPP4, saxagliptin ; (iii) treatment with the thiazolidinedione, pioglitazone; (iv) treatment with the biguanide, metformin.
To examine the effect of the following pharmacologic interventions on beta cell function, insulin sensitivity, and glucose tolerance status in individuals with isolated impaired fasting glucose (IFG): (i) treatment with the renal SGLT2 inhibitor, dapagliflozin; (ii) treatment with the DPP4 inhibitor, saxagliptin; (iii) treatment with the thiazolidinedione, pioglitazone; (iv) treatment with the biguanide, metformin.
To examine the effect of the following pharmacologic interventions on beta cell function, insulin sensitivity, and glucose tolerance status in individuals with combined impaired glucose tolerance (IGT) plus impaired fasting glucose (IFG): i) treatment with the renal SGLT2 inhibitor, dapagliflozin; (ii) treatment with the DPP4 inhibitor, saxagliptin; (iii) treatment with the thiazolidinedione, pioglitazone; (iv) treatment with the biguanide, metformin.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

700 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Study Start Date :

Jan 1, 2014

Anticipated Primary Completion Date :

Jul 1, 2023

Anticipated Study Completion Date :

Jul 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Healthy normal glucose tolerance (NGT) subjects Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
Active Comparator: Isolated IGT with Dapagliflozin Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day	Drug: Dapagliflozin 10mg/day Other Names: farxiga
Active Comparator: Isolated IGT with Saxagliptin Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day	Drug: Saxagliptin 5mg/day Other Names: onglyza
Active Comparator: Isolated IGT with Pioglitazone Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two	Drug: Pioglitazone the dose will increase from 15 mg/day to 30 mg/day at month two Other Names: actos
Active Comparator: Isolated IGT with Metformin Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.	Drug: Metformin starting at 1000 mg/day and increased to 2000 mg/day at month 2. Other Names: glucophage
Active Comparator: Isolated IFG with Dapagliflozin Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive dapagloflozin, 10mg/day	Drug: Dapagliflozin 10mg/day Other Names: farxiga
Active Comparator: Isolated IFG with Saxagliptin Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive saxagliptin, 10mg/day	Drug: Saxagliptin 5mg/day Other Names: onglyza
Active Comparator: Isolated IFG with Pioglitazone Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two	Drug: Pioglitazone the dose will increase from 15 mg/day to 30 mg/day at month two Other Names: actos
Active Comparator: Isolated IFG with Metformin Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.	Drug: Metformin starting at 1000 mg/day and increased to 2000 mg/day at month 2. Other Names: glucophage
Active Comparator: IGT plus IFG with Dapagliflozin Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day	Drug: Dapagliflozin 10mg/day Other Names: farxiga
Active Comparator: IGT plus IFG with Saxagliptin Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day	Drug: Saxagliptin 5mg/day Other Names: onglyza
Active Comparator: IGT plus IFG with Pioglitazone Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two	Drug: Pioglitazone the dose will increase from 15 mg/day to 30 mg/day at month two Other Names: actos
Active Comparator: IGT plus IFG with Metformin Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.	Drug: Metformin starting at 1000 mg/day and increased to 2000 mg/day at month 2. Other Names: glucophage

Outcome Measures

Primary Outcome Measures

Beta cell function [24 months after treatment phase begins]
Beta cell function will be measured as insulin secretion during the hyperglycemic clamp (mean plasma insulin concentration in uU/ml) multiplied by insulin sensitivity measured with the euglycemic insulin clamp (mg/kg.min).
Insulin sensitivity [24 months after treatment phase begins]
Insulin sensitivity will be measured with the euglycemic insulin clamp and expressed as mg/kg.min.
Glucose tolerance status [24 months after treatment phase begins]
Glucose tolerance status will be evaluated by measuring the HbA1c which is a measure of the average of the amount of glucose attached to hemoglobin over the past 3 months, expressed as a percentage.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

NGT subjects will serve as controls and will be matched in age, gender, ethnicity, and BMI to IGT and IFG subjects

Male or female subjects between the ages of 18 and 65 years of age, inclusive, at Screening.
FPG < 100 mg/dl and 2-h PG < 140 mg/dl
BMI = 24-40 kg/m2;
Stable body weight (±4lbs) over the preceding 3 months
Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data
Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose):

Oral contraceptive
Injectable progesterone
Subdermal implant
Spermicidal foam/gel/film/cream/suppository
Diaphragm with spermicide
Copper or hormonal containing IUD
Sterile male partner vasectomized > 6 month pre-dosing.

Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures.

Exclusion Criteria:

Recent (i.e., within three (3) months prior to Screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological, or clinically significant neurological disease.
Subjects with a family history of diabetes in a first degree relative
BMI of less than 24 or greater than 40 kg/m2
Unstable body weight (change of greater than ±4lbs over the preceding 3 months
Subjects participating in an excessively heavy exercise program
Subject with a feeding/sleeping schedule different from a daytime feeding/night time sleeping schedule
Subjects taking medications known to alter glucose metabolism (with the exception of metformin and/or pioglitazone) or which effect brain neurosynaptic function are excluded.
Subjects with evidence of major organ system disease as determined by physical exam, history, and screening laboratory data
Pregnant subjects or subjects unwilling to use birth control during their study enrollment
Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Subjects with hematuria will be excluded.
Subjects with evidence or prior history of heart failure will be excluded
Subjects with family history of pancreatic, bladder, and breast cancer will be excluded.
Subjects with history of pancreatitis will be excluded.
Subjects with eGFR < 60 ±5 ml/min.1.73m2 will be excluded.
Subjects with elevated serum creatinine (>1.5 mg/dl males/1.4 mg/dl females) will be excluded.
Subjects with a history of orthostatic hypotension (>15/10 mmHg) will be excluded.
Subjects with liver enzymes (ALT, AST) >3-fold above upper normal limit will be excluded.
Subjects with a history of hypersensitivity to pioglitazone, dapagliflozin, or Saxagliptin will be excluded.